BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 35228445)

  • 1. [Production of antiviral vaccines using a silkworm-baculovirus expression system].
    Kusakabe T
    Nihon Yakurigaku Zasshi; 2022; 157(2):128-133. PubMed ID: 35228445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of antiviral vaccine antigens using a silkworm-baculovirus expression system.
    Kusakabe T
    J Pharmacol Sci; 2023 Mar; 151(3):156-161. PubMed ID: 36828618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants.
    Masuda A; Lee JM; Miyata T; Mon H; Sato K; Oyama K; Sakurai Y; Yasuda J; Takahashi D; Ueda T; Kato Y; Nishida M; Karasaki N; Kakino K; Ebihara T; Nagasato T; Hino M; Nakashima A; Suzuki K; Tonooka Y; Tanaka M; Moriyama T; Nakatake H; Fujita R; Kusakabe T
    Front Immunol; 2021; 12():803647. PubMed ID: 35095889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Integrated Platform for Serological Detection and Vaccination of COVID-19.
    Wei SC; Hsu WT; Chiu CH; Chang FY; Lo HR; Liao CY; Yang HI; Chou YC; Tsai CH; Chao YC
    Front Immunol; 2021; 12():771011. PubMed ID: 35003088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
    van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP
    mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.
    Gudadappanavar AM; Benni J
    J Basic Clin Physiol Pharmacol; 2020 Sep; 31(6):. PubMed ID: 32924964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Coronavirus Vaccines against Syndrome Coronavirus 2 (SARS-CoV-2) and Its New Variants.
    Abdi Ghavidel A; Rojhannezhad M; Kazemi B; Bandehpour M
    Iran J Allergy Asthma Immunol; 2021 Dec; 20(6):647-671. PubMed ID: 34920649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Killed whole-genome reduced-bacteria surface-expressed coronavirus fusion peptide vaccines protect against disease in a porcine model.
    Maeda DLNF; Tian D; Yu H; Dar N; Rajasekaran V; Meng S; Mahsoub HM; Sooryanarain H; Wang B; Heffron CL; Hassebroek A; LeRoith T; Meng XJ; Zeichner SL
    Proc Natl Acad Sci U S A; 2021 May; 118(18):. PubMed ID: 33858942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system.
    Fujita R; Hino M; Ebihara T; Nagasato T; Masuda A; Lee JM; Fujii T; Mon H; Kakino K; Nagai R; Tanaka M; Tonooka Y; Moriyama T; Kusakabe T
    Biochem Biophys Res Commun; 2020 Aug; 529(2):257-262. PubMed ID: 32703420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of classical swine fever virus envelope glycoprotein E2 as recombinant polyhedra in baculovirus-infected silkworm larvae.
    Lee KS; Sohn MR; Kim BY; Choo YM; Woo SD; Yoo SS; Je YH; Choi JY; Roh JY; Koo HN; Jin BR
    Mol Biotechnol; 2012 Mar; 50(3):211-20. PubMed ID: 21706129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
    Sharma D
    Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development.
    Ita K
    Arch Med Res; 2021 Jan; 52(1):15-24. PubMed ID: 32950264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
    Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
    Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.